HIF2A | ApexOnco - Clinical Trials news and analysis

x

“OncologyPipeline is my favorite CI tool”

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Trial results

31 January 2024

Novartis calls time on TIM-3 and HIF2α

The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.

Subscribe to HIF2A